Loading...
XSHE
300254
Market cap352mUSD
Oct 09, Last price  
9.28CNY
1D
1.09%
1Q
12.62%
Jan 2017
-51.89%
IPO
-22.76%
Name

Shanxi C&Y Pharmaceutical Group Co Ltd

Chart & performance

D1W1MN
XSHE:300254 chart
P/E
96.05
P/S
2.74
EPS
0.10
Div yield, %
—
Shrs. gr., 5y
1.44%
Rev. gr., 5y
-1.32%
Revenues
871m
+2.86%
203,666,798243,618,734319,552,530310,780,744361,500,206513,510,738653,655,235683,934,855746,076,863938,927,9851,136,495,6671,131,801,410848,072,527930,374,948930,374,947828,997,054828,997,054799,305,103846,606,161870,786,344
Net income
25m
-41.10%
13,035,04428,900,35647,983,62235,344,03525,801,04627,112,44240,997,50122,900,03530,147,71021,673,4227,241,0875,296,795-262,367,4440-91,437,5550-118,520,30725,195,59142,190,12424,850,904
CFO
97m
+36.41%
0105,550,37552,032,4634,750,02235,051,20580,581,53382,191,77715,443,10841,650,14040,103,87838,440,74369,631,646096,921,05874,876,11637,814,36770,940,60496,767,872
Dividend
Jul 11, 20190.02 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ShanXi C&Y Pharmaceutical Group Co., Ltd. is a global pharmaceutical enterprise dedicated to the research, development, production, and distribution of a diverse range of medicines. Its operations span key markets including China, the United States, and Hong Kong, alongside other international regions. The company's extensive product catalog features specialized solutions for maternal and infant care, urological health, and infectious diseases, as well as traditional Chinese remedies and dermatological treatments. Additionally, it diversifies its offerings with tea bag products. Founded in 2005, the organization underwent a name change in September 2014, evolving from Shanxi C&Y Pharmaceutical Co., Ltd. to its current designation. ShanXi C&Y Pharmaceutical Group Co., Ltd. maintains its corporate headquarters in Shanghai, China.

Key people

Qun Zhao
President, Director · since 2021
Hairong Zhong
Vice Chairman of the Board · since 2021
Yanjie He
Chief Financial Officer · since 2018
Kairui Luo
Vice President · since 2024
Han Yin
Vice President · since 2024
Yingmin Yu
Chief Engineer · since 2016
Lequn Huang
Chairman of the Board · since 2021
Junxian Yu
Vice President, Secretary of the Board · since 2026
Hao Gao
Independent Director · since 2020
Dong Huang
Independent Director · since 2026
Tao Ju
Independent Director · since 2020
Independent Director · since 2022
Jinfeng Wu
Independent Director · since 2026
Independent Director · since 2026
Independent Director · since 2023
IPO date
Aug 19, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT